Inhaled hydrogen gas therapy for prevention of testicular ischemia/reperfusion injury in rats.
Jae-Won Lee, Jong-In Kim, Young-Ah Lee, Dong-Hun Lee, Chang-Seon Song, Yoon Ju Cho, Jin Soo Han · Journal of pediatric surgery · 2012
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This study evaluated whether 2% hydrogen (H(2)) gas therapy protects against testicular ischemia/reperfusion injury which results in increased formation of reactive oxygen species and/or reactive nitrogen species, leading to testicular apoptosis and impaired spermatogenesis. These results are preclinical and suggest molecular hydrogen's therapeutic potential in the condition studied. Further human research is needed to establish clinical effectiveness.
What the Researchers Studied
This study evaluated whether 2% hydrogen (H(2)) gas therapy protects against testicular ischemia/reperfusion injury which results in increased formation of reactive oxygen species and/or reactive nitrogen species, leading to testicular apoptosis and impaired spermatogenesis.
How Molecular Hydrogen Was Used
The source material available to H2HUBB did not provide enough detail to identify the molecular hydrogen administration method.
What the Researchers Found
Compared to the sham group (A), germ cellular apoptosis and lipid peroxidation in the ischemia group (B) were significantly increased with abnormal morphology and impaired spermatogenesis.
H₂ Mechanisms / Biological Findings
The source material reviewed did not establish a specific molecular hydrogen mechanism for the reported findings.
Authors’ Conclusion
The authors concluded that inhalation of 2% H(2) gas may be a promising therapy with anti-apoptotic and anti-oxidant properties in cases of testicular ischemia/reperfusion injury.